Efbemalenograstim Alfa Dosage

Usual Adult Dose for Febrile Neutropenia

20 mg subcutaneously once per chemotherapy cycle

Comments:

• This drug should NOT be administered within 14 days before and less than 24 hours after cytotoxic chemotherapy.
• This product contains natural rubber latex, which may cause allergic reactions. Individuals with latex allergies should not administer this product.
• If injecting into the abdomen, avoid a 2-inch diameter circle around the navel.

Use: This drug is indicated to reduce the risk of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs

Renal Dose Adjustments

Dose adjustment may be required; however, no specific guidelines have been suggested.

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Serious allergic reactions to granulocyte stimulating factors such as efbemalenograstim alfa-vuxw, pegfilgrastim, or filgrastim products

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Before use, remove the carton from the refrigerator, keeping the prefilled syringe inside, for at least 30 minutes to allow the product to reach room temperature.
• Discard any product left at room temperature for more than 48 hours.
• Before administration, visually inspect for particulate matter and discoloration. Do not administer if discoloration or particulates are observed.
• Rotate injection sites. Do not inject into scar tissue or areas that are reddened, inflamed, or swollen.
• The manufacturer product information should be consulted.

Storage requirements:

• Store at 2C to 8C (36F to 46F), protected from light.
• Do not shake.
• Do not freeze. Discard the syringe if it is frozen.
• Syringes that have been stored at room temperature for over 48 hours should be discarded.

General:

• This drug is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Monitoring:
Cardiovascular: Capillary leak syndrome
Hematologic: Platelet counts, CBC
Oncologic: Myelodysplastic syndrome (MDS), Acute myeloid leukemia (AML)

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
• Rupture or enlargement of the spleen may occur. If left upper quadrant abdominal pain or left shoulder pain occurs, report it to your healthcare provider immediately.
• Dyspnea, with or without fever, progressing to acute respiratory distress syndrome, may occur. Report dyspnea to your healthcare provider immediately.
• Serious allergic reactions may occur. Seek immediate medical attention if signs or symptoms of hypersensitivity reaction occur.
• In patients with sickle cell disease, sickle cell crisis and death have been reported with the use of human granulocyte colony-stimulating factors. Potential risks and benefits for patients with sickle cell disease should be discussed prior to the administration of this drug.
• If signs or symptoms of glomerulonephritis, aortitis, or capillary leak syndrome occur, report them to your healthcare provider immediately.
• There may be an increased risk of myelodysplastic syndrome and/or acute myeloid leukemia in patients with breast and lung cancer who receive this drug in conjunction with chemotherapy and/or radiation therapy. Report to your physician the signs and symptoms of MDS or AML.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer